Paul Autenried - Bristol-Myers Squibb Senior Vice President - Enterprise Services, CIO
President
Mr. Paul von Autenried is Chief Information Officer, Senior Vice President of the Company. From 2011 to 2012 Senior Vice President and Chief Information Officer 2012 to 2016 Senior Vice President, Enterprise Services and Chief Information Officer 2016 to present Senior Vice President, Chief Information Officer. since 2016.
Age | 56 |
Tenure | 8 years |
Phone | 212-546-4000 |
Web | http://www.bms.com |
Similar Executives
Showing other executives | PRESIDENT Age | ||
Ruud Dobber | AstraZeneca PLC ADR | N/A | |
DavidAlexandre Gros | Sanofi ADR | 42 | |
Bahija Jallal | AstraZeneca PLC ADR | 55 | |
Claire Thomas | GlaxoSmithKline PLC ADR | N/A | |
Pam Cheng | AstraZeneca PLC ADR | 54 | |
Shuji Handa | Daiichi Sankyo | N/A | |
Hiroyuki Okuzawa | Daiichi Sankyo | 61 | |
Katarina Ageborg | AstraZeneca PLC ADR | N/A | |
Dominique Carouge | Sanofi ADR | N/A | |
MarieFrance Tschudin | Novartis AG ADR | 53 | |
Stefan Oelrich | Sanofi ADR | 49 | |
Andre Wyss | Novartis AG ADR | 50 | |
James Bradner | Novartis AG ADR | 49 | |
William Sibold | Sanofi ADR | 51 | |
Shah Hussain | GlaxoSmithKline PLC ADR | 48 | |
Yoshitsugu Shitaka | Astellas Pharma | N/A | |
Susanne Schaffert | Novartis AG ADR | 54 | |
Jennifer Brendelto | Bayer Aktiengesellschaft | N/A | |
Shreeram MD | Novartis AG ADR | 61 | |
Olivier Charmeil | Sanofi ADR | 55 | |
JeanBaptiste Chatillon | Sanofi ADR | 59 |
Bristol Myers Squibb Leadership Team
Elected by the shareholders, the Bristol-Myers Squibb's board of directors comprises two types of representatives: Bristol-Myers Squibb inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol-Myers. The board's role is to monitor Bristol-Myers Squibb's management team and ensure that shareholders' interests are well served. Bristol-Myers Squibb's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol-Myers Squibb's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ann Powell, Chief Human Resource Officer, Senior Vice President | ||
Togo West, Independent Director | ||
Karen Vousden, Director | ||
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer | ||
Alan Lacy, Independent Director | ||
Robert Bertolini, Independent Director | ||
Jose Baselga, Independent Director | ||
Charles Bancroft, CFO, Executive Vice President | ||
Gerald Storch, Independent Director | ||
Louis Schmukler, President - Global Manufacturing and Supply | ||
Michael Grobstein, Independent Director | ||
Christopher Boerner, Executive Vice President and Chief Commercial Officer | ||
John Elicker, Senior Vice President - Public Affairs and Investor Relations | ||
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer | ||
Karen Santiago, Senior Vice President Controller | ||
Giovanni Caforio, COO, Director | ||
Vicki Sato, Independent Director | ||
Emmanuel Blin, Senior Vice President Chief Strategy Officer | ||
Joseph Caldarella, Senior Vice President Corporate Controller | ||
Laurie Glimcher, Independent Director | ||
Murdo Gordon, Executive Vice President Chief Commercial Officer | ||
Lamberto Andreotti, CEO, Director | ||
Thomas Lynch, Independent Director | ||
Dinesh Paliwal, Independent Director | ||
Lewis Campbell, Independent Director | ||
Theodore Samuels, Independent Director | ||
Samuel Moed, Senior Vice President - Strategic Planning and Analysis | ||
Matthew Emmens, Independent Director | ||
Ann Judge, Senior Vice President - Global Human Resources | ||
Sandra Leung, General Counsel, Corporate Secretary | ||
Paul Autenried, Senior Vice President - Enterprise Services, CIO | ||
Francis Cuss, Executive Vice President Chief Scientific Officer | ||
Paul Biondi, Senior Vice President Head - Business Development | ||
Peter Arduini, Independent Director |
Bristol-Myers Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bristol-Myers Squibb a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Revenue | 46.38 B | |||
EBITDA | 20.1 B | |||
Net Income | 7.01 B | |||
Cash And Equivalents | 6.07 B | |||
Cash Per Share | 3.72 X | |||
Total Debt | 39.6 B | |||
Debt To Equity | 59.40 % | |||
Current Ratio | 1.40 X | |||
Book Value Per Share | 7.55 X | |||
Cash Flow From Operations | 16.21 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bristol-Myers Squibb in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bristol-Myers Squibb's short interest history, or implied volatility extrapolated from Bristol-Myers Squibb options trading.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Bristol-Myers Pink Sheet
If you are still planning to invest in Bristol Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol-Myers Squibb's history and understand the potential risks before investing.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |